ApprovedFDA approval

Yuviwel (navepegritide)

Ascendis Pharma (ASND)

Marketer take

A once-weekly option in achondroplasia versus daily Voxzogo injections, with oral infigratinib due Feb 4, 2027, so pediatric endocrinologists and families will weigh dosing frequency and route.

Sponsor company
Ascendis Pharma (ASND)
Indication
To increase linear growth in pediatric patients 2 years and older with achondroplasia with open epiphyses
Therapeutic area
Endocrinology, Rare disease
Event
FDA approval
Date
Feb 27, 2026
Status
Approved
Source
FDA page
Last verified
Nov 15, 2026

Dates and status come from the linked public source as of the last verified date. Spot an error or have an update?

Get alerts when FDA dates move